Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

7.51
Delayed Data
As of Jun 23
 -0.09 / -1.18%
Today’s Change
4.00
Today|||52-Week Range
11.72
-13.08%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 2
2016
Quarter 3
2016
Quarter 4
2016
Quarter 1
2017
Revenue and IncomeNet Revenues8.5M53.9M4.7M2.3M
 
 
 
 
 
Depreciation And Amortization747.0K362.0K218.0K256.0K
 
 
 
 
 
 
Operating ExpensesGross Income----------
General Expenses12.8M16.7M15.1M15.4M
 
 
 
 
 
Research And Development8.0M9.8M10.6M10.0M
 
 
 
 
 
Total Operating Expenses13.6M17.0M15.3M15.7M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-5.1M36.8M-10.7M-13.4M
 
 
 
 
 
Extraordinary Credit0.000.006.0M0.00
 
 
Extraordinary Charge-600.0K-600.0K0.00-1.9M
 
 
 
 
Interest Expense On Debt0.000.00800.0K1.3M
 
 
 
Other Expenses0.000.00-34.0K0.00
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-5.7M36.3M-5.4M-16.4M
 
 
 
 
 
Income Taxes0.000.00-1.8M0.00
 
 
Minority Interest-19.0K-21.0K-15.0K0.00
 
 
 
 
Net Income-5.6M36.3M-7.2M-16.4M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS69.9M70.0M70.1M70.2M
 
 
 
 
 
Shares To Calculate EPS Diluted69.9M70.3M70.1M70.2M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.08$0.52-$0.10-$0.23
 
 
 
 
 
EPS Diluted-$0.08$0.52-$0.10-$0.23